Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung, on behalf of the Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2026;32(1):1-52. Published online October 23, 2025
Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Infection and Public Health.2026; 19(2): 103076. CrossRef
Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection Jeayeon Park, Jae Yoon Jeong, Soon Sun Kim, Jae Hyun Yoon, Hyuk Soo Eun, Jonggi Choi, Ki Tae Yoon, Young Kul Jung, Soo Young Park, Geum-Youn Gwak, Do Young Kim, Ji Hoon Kim, Jin-Woo Lee, Tae Yeob Kim, Jeong Won Jang, Su Jong Yu World Journal of Gastroenterology.2026;[Epub] CrossRef
2025 KASL clinical practice guidelines for management of hepatitis C Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study Jung Hee Kim, Sung-Eun Kim, Do Seon Song, Hee Yeon Kim, Eileen L. Yoon, Ji Won Park, Tae Hyung Kim, Young-Kul Jung, Ki Tae Suk, Hyung Joon Yim, Jung Hyun Kwon, Sung Won Lee, Seong Hee Kang, Moon Young Kim, Soung Won Jeong, Jae-Young Jang, Jeong Ju Yoo, Sa Annals of Medicine.2025;[Epub] CrossRef
Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong Gut and Liver.2025; 19(5): 725. CrossRef
Temporal Dynamics and Treatment Outcomes of Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Multicenter Retrospective Study from South Korea Jae Yoon Jeong, Su Jong Yu, Jeayeon Park, Na Ryung Choi, Soon Sun Kim, Jae Hyun Yoon, Hyuk Soo Eun, Jonggi Choi, Ki Tae Yoon, Young Kul Jung, Soo Young Park, Geum-Youn Gwak, Tae Yeob Kim, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Jin-Woo Lee, Jeong Won Jan Gut and Liver.2025; 19(6): 868. CrossRef
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update Graham S Cooke, Barnaby Flower, Evan Cunningham, Alison D Marshall, Jeffrey V Lazarus, Adam Palayew, Jidong Jia, Rakesh Aggarwal, Mamum Al-Mahtab, Yashuito Tanaka, Sook-Hyang Jeong, Kittiyod Poovorawan, Imam Waked, Lindsey Hiebert, Pham M Khue, Jason Greb The Lancet Gastroenterology & Hepatology.2024; 9(4): 346. CrossRef
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2024; 39(6): 1155. CrossRef
Toward hepatitis C virus elimination using artificial intelligence Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Occurrence of Liver Cancer in People without Traditional Risk Factors Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho Korean Journal of Clinical Geriatrics.2023; 24(1): 41. CrossRef
Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Yun Soo Hong, Juhee Cho, Geum-Youn Gwak BMC Medicine.2022;[Epub] CrossRef
Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study Gwang Hyeon Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Han Chu Lee, Jeong Won Jang, Moran Ki, Hwa Young Choi, Dahye Baik, Sook-Hyang Jeong World Journal of Gastroenterology.2022; 28(30): 4182. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital Mi Seon Park, Young-Mo Yang, Ki Hyun Park, Hyonok Yoon, Ju Sin Kim, Eun Joo Choi Korean Journal of Clinical Pharmacy.2022; 32(3): 191. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease Seung Hwan Shin, Sang Hyoung Park The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Report on the External Quality Assessment Scheme for Molecular Microbiology, Hepatitis Virus 1, 2 (2016–2021) Hee-Won Moon, Tae Hwan Lee, Jong Do Seo Journal of Laboratory Medicine and Quality Assurance.2022; 44(4): 191. CrossRef
Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events Joo Hyun Oh, Myung Ji Goh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik Digestive Diseases and Sciences.2021; 66(8): 2816. CrossRef
Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea Dae Hyun Lim, Jae Yoon Jeong, Seongwoo Nam, Jongkyoung Choi, Hyeok Choon Kwon, Yong Bum Yoon, Yeonjae Kim, BumSik Chin Journal of Korean Medical Science.2021;[Epub] CrossRef
Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals Dong Hoon Lee, Soo Hyung Ryu, Hee jun Myung, Yun Jae Shin, Si Hyeong Lee, Tae Young Park, Jeong Seop Moon The Korean Journal of Gastroenterology.2021; 77(2): 88. CrossRef
Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi PLOS ONE.2021; 16(8): e0255624. CrossRef
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho Gut and Liver.2021; 15(3): 440. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini PLOS ONE.2021; 16(2): e0246143. CrossRef
Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival Min Woo Lee, Danbee Kang, Hyo Keun Lim, Juhee Cho, Dong Hyun Sinn, Tae Wook Kang, Kyoung Doo Song, Hyunchul Rhim, Dong Ik Cha, David S. K. Lu European Radiology.2020; 30(4): 2391. CrossRef
Kidney disease in patients with chronic liver disease Jae Hyun Chang Journal of the Korean Medical Association.2020; 63(1): 14. CrossRef
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara, Jason Blacka PLOS ONE.2020; 15(6): e0234811. CrossRef
Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak International Journal of Epidemiology.2020; 49(5): 1562. CrossRef
Development and Evaluation of an Antiviral Agent Medication Adherence Education Program for Patients with Chronic Hepatitis C Hoo Jeung Cho, Euna Park International Journal of Environmental Research and Public Health.2020; 17(18): 6518. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong Gut and Liver.2020; 14(6): 775. CrossRef
A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis Jae Hyun Yoon, Sun Min Kim, Gaeun Kang, Hee Joon Kim, Chung Hwan Jun, Sung Kyu Choi Medicine.2019; 98(39): e17343. CrossRef
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study Seong Jun Park, Ah Ran Kim, Won Hyeok Choe, Jeong Han Kim, Byung Chul Yoo, So Young Kwon The Korean Journal of Gastroenterology.2018; 72(4): 197. CrossRef
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.
Citations
Citations to this article as recorded by
Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study Hyun Joon Park, Hoyoung Wang, Joonho Jeong, Kwang Il Seo, Jung Woo Shin, Neung Hwa Park Medicine.2025; 104(47): e46079. CrossRef
Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study Bo Ram Sung, Sang Goon Shim, Kwang Min Kim, Jung Won Lee, Jun Young Kim, Bo Kyeong Lee, Cheon Hoo Jun, Byung Soo Kwan Medicine.2025; 104(50): e46449. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Viruses.2024; 16(12): 1899. CrossRef
Characterization of Incident Hepatitis C Virus Infection among People Living with HIV in a HIV Clinic in Korea BumSik Chin, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, Min-Kyung Kim, Jae Yoon Jeong, Hyeokchoon Kwon, Seongwoo Nam Infection & Chemotherapy.2024; 56(4): 544. CrossRef
Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study Byung Soo Kwan, Sung Min Kong, Sang Goon Shim, Kwang Min Kim, Gil Jong Yu, Jae Jin Lee, Jin Dong Kim Arab Journal of Gastroenterology.2023; 24(2): 104. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong The Korean Journal of Internal Medicine.2022; 37(5): 958. CrossRef
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study Yeo Wool Kang, Yang Hyun Baek, Sung Wook Lee, Sung-Jae Park, Jun Sik Yoon, Ki Tae Yoon, Youngmi Hong, Nae-Yun Heo, Kwang Il Seo, Sang Soo Lee, Hyun Chin Cho, Jung Woo Shin Journal of Korean Medical Science.2021;[Epub] CrossRef
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials Jeong Heo, Yoon Jun Kim, Jin-Woo Lee, Ji Hoon Kim, Young-Suk Lim, Kwang-Hyub Han, Sook-Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda M. Fredrick, Negar Niki Alami, Armen Asatryan, Do Hyun Kim, Seung Woon Paik, Youn-Jae Lee Gut and Liver.2021; 15(6): 895. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals Pil Soo Sung, Eui-Cheol Shin International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko The Korean Journal of Internal Medicine.2020; 35(3): 559. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi Gut and Liver.2019; 13(5): 549. CrossRef
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real‐world setting? Jae Hyun Yoon, Chung Hwan Jun, Ji Ho Seo, Hyun A Cho, Sung Bum Cho, Sung Kyu Choi, Ju Yeon Cho, Man Woo Kim, Sung Wook Lim Journal of Digestive Diseases.2019; 20(1): 31. CrossRef
Background/Aims Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been used to treat chronic hepatitis C without severe adverse effects and have achieved a sustained viral response (SVR) rate of 80-90% with short treatment duration. We were interested to determine whether all patients who failed to respond to or were ineligible for interferon-based therapy could be treated with DAAs.
Methods Medical records of patients with positive serum anti-hepatitis C virus (HCV) or HCV RNA between January 2009 and December 2013 were reviewed. Demographic, clinical, and treatment data were collected for analysis.
Result s: A total of 876 patients were positive for both anti-HCV and HCV RNA. Of these, 244 patients were eligible for interferon, although this was associated with relapse in 39 (16%) of patients. In total, 130 patients stopped interferon therapy (67% adverse effects, 28% non-adherent, 4% malignancy, 1% alcohol abuse) and 502 patients were ineligible (66% medical contraindications, 25% non-adherent, 5% socioeconomic problems). Among 671 patients who were ineligible for or failed to respond to interferon therapy, more than 186 (27.7%) could not be treated with DAA due to financial, social, or cancer-related conditions.
Conclusions Newly developed DAAs are a promising treatment for patients with chronic hepatitis C who are ineligible for or failed to respond to interferon-based therapy. Nevertheless, not all chronic hepatitis C patients can be treated with DAAs due to various reasons.
Citations
Citations to this article as recorded by
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Viruses.2024; 16(12): 1899. CrossRef
Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection Ratna Chowdhury, Wardah Rashid, Taranpreet Singh, Abdur Rehman, Nida F Daterdiwala, Varaidzo Mkosi, Bhumikala Limbu, Syeda Alliza Bukhari, Afif Ramadhan, Muath M Dabas, Abdullah Shehryar, Ramadan Khan Cureus.2024;[Epub] CrossRef
Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation Christina Sølund, Sofie Hallager, Martin S. Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B. Krarup, Birgit T. Røge, Peer B. Christensen, Alex L. Laursen, Jan Gerstoft, Erika Bélard, Lone G. Madsen, Kristian Schønning, Anders G. Pedersen, Jens Bukh, Nina Wei Scandinavian Journal of Gastroenterology.2018; 53(7): 849. CrossRef
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges Reza Taherkhani, Fatemeh Farshadpour World Journal of Hepatology.2017; 9(33): 1239. CrossRef
First
Prev
